SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). (SUSTAINCSX)
Heart Disease

About this trial
This is an interventional treatment trial for Heart Disease focused on measuring antioxidants, selenium, heart disease, cardiac surgery, perioperative
Eligibility Criteria
Inclusion Criteria:
- Adult patients (>/=18 years of age)
Scheduled to undergo elective or urgent cardiac surgery with the use of cardiopulmonary bypass (CPB) and cardioplegic arrest that exhibit a high perioperative risk profile as defined by the presence of one or more of the following:
- a) Planned valve surgery combined with CABG or multiple valve replacement/repair surgeries or combined cardiac surgical procedures involving the thoracic aorta; OR
- b) Any cardiac surgery with a high perioperative risk profile, defined as a predicted operative mortality of ≥ 5% (EuroSCORE II).
Exclusion Criteria:
We will exclude patients who meet any of the following criteria:
- Isolated procedures (CABG only or valve)
- Known hypersensitivity to sodium-selenite or to any of the constituents of the solution.
- Renal failure requiring dialysis at the point of screening.
- Chronic liver disease as evidenced by a pre-operative total bilirubin >2 mg/dl or 34 umol/L.
- Disabling neuropsychiatric disorders (severe dementia, severe Alzheimer's disease, advanced Parkinson's disease).
- Pregnancy or lactation period.
- Simultaneous participation in another clinical trial of an experimental therapy (co-enrolment acceptable in observational studies or randomized trials of existing therapies if permitted by both steering committees and local ethics boards).
- Patients undergoing heart transplantation or preoperative planned LVAD insertion or complex congenital heart surgery.
- Alternate contacts of investigators (required by German Regulatory Authorities).
Sites / Locations
- Hamilton General Hospital
- London Health Sciences Centre
- University of Ottawa Heart Institute
- Sunnybrook Health Sciences Centre
- St. Michael's Hospital
- Toronto General Hospital
- Institut de cardiologie de Montreal
- Sir Mortimer B. Davis Jewish General Hospital
- McGill University Health Centre
- Sacre Coeur
- IUCPQ
- Centre de recherche CIUSSS de l'Estrie CHUS
- RWTH Aachen University Hospital
- Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn
- Universitätsklinikum Frankfurt
- Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg
- Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen
- University Medical Center Schleswig-Holstein
- Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln
- Klinik für Anästhesiologie Universitätsmedizin Mainz
- Klinik für Anästhesiologie Klinikum der Universität München
- Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum
- Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Placebo
sodium selenite
Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
High-dose sodium-selenite will be administered to subjects intravenously: 1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first.